F-41 Sorafenib for hepatocellular carcinoma (HCC) in patients with established cirrhosis: impact of the type of recruiting unit and predictors of survival
Titel:
F-41 Sorafenib for hepatocellular carcinoma (HCC) in patients with established cirrhosis: impact of the type of recruiting unit and predictors of survival
Auteur:
Inghilesi, A. Antonuzzo, L. Gallori, D. Forte, P. Tomcikova, D. Arena, U. Colagrande, S. Pradella, S. Fani, B. Gianni, E. Boni, L. Laffi, G. Di Costanzo, F. Marra, F.